Scarica l'app Stockscreener
1.1999
0.42%
-0.0051
Tharimmune Inc Borsa (THAR) Ultime notizie
Tharimmune announces board retirements ahead of annual meeting By Investing.com - Investing.com South Africa
Press Release Distribution & PR Platform - ACCESS Newswire
Tharimmune (THAR) Expands Board with New Appointment | THAR Stoc - GuruFocus
Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors - standard-journal.com
Healthcare Investment Expert Managing $150M Portfolio Strengthens Tharimmune's Strategic Leadership - Stock Titan
Tharimmune reports data on new biparatopic biologics - BioWorld MedTech
THAR stock touches 52-week low at $1.12 amid sharp annual decline By Investing.com - Investing.com South Africa
THAR stock touches 52-week low at $1.12 amid sharp annual decline - Investing.com Australia
Tharimmune Reports Preclinical Data for Dual-Target Biologics - MarketScreener
Tharimmune Announces Positive Data With Novel Biparatopic PD-1/VEGF & Multispecific HER2/HER3 Biologics Leveraging Proprietary Epiclick(TM) Technology - MarketScreener
Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology - Weatherford Democrat
Breakthrough Cancer Drug Shows Superior Design: Tharimmune's Dual-Target Biologic Outperforms Competition - Stock Titan
Tharimmune receives Nasdaq non-compliance notice - Investing.com Australia
Tharimmune receives Nasdaq non-compliance notice By Investing.com - Investing.com Canada
Tharimmune, Inc. (NASDAQ:THAR) Short Interest Update - Defense World
Virtu Financial LLC Makes New Investment in Tharimmune, Inc. (NASDAQ:THAR) - Defense World
THAR stock touches 52-week low at $1.2 amid sharp annual decline By Investing.com - Investing.com South Africa
Jayud Global Logistics Ltd (JYD): What Makes The Stock Good? - Marketing Sentinel
THAR stock touches 52-week low at $1.2 amid sharp annual decline - Investing.com
Tharimmune Says FDA Requires No Additional Trials of TH104 Against Opioid Exposure - MarketScreener
FDA greenlights Tharimmune’s drug application pathway - Investing.com India
Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure - Weatherford Democrat
FDA Fast-Tracks Tharimmune's Revolutionary Opioid Defense Drug: No Clinical Trials Needed - Stock Titan
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha - Weatherford Democrat
Game-Changing Oral Alternative to Injectable Antibody Achieves Key Milestone - Stock Titan
Tharimmune leverages Epiclick platform to expand pipeline - BioWorld Online
Hillstream Biopharma stock hits 52-week low at $1.36 - Investing.com
Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology - Markets Insider
Tharimmune unveils novel cancer treatment HS1940 - Investing.com India
Tharimmune unveils novel cancer treatment HS1940 By Investing.com - Investing.com South Africa
Short Interest in Tharimmune, Inc. (NASDAQ:THAR) Declines By 58.6% - Defense World
Short Interest in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Expands By 148.7% - Defense World
Tharimmune appoints new CFO following resignation By Investing.com - Investing.com Canada
Tharimmune Says Thomas Hess Resigns As CFO -February 27, 2025 at 05:34 pm EST - Marketscreener.com
Tharimmune Says Thomas Hess Resigns As CFO - TradingView
Tharimmune appoints new CFO following resignation - Investing.com
Hillstream Biopharma stock hits 52-week low at $1.83 By Investing.com - Investing.com Canada
Hillstream Biopharma stock hits 52-week low at $1.83 - Investing.com
Financial Analysis: ObsEva (NASDAQ:OBSV) & Tharimmune (NASDAQ:THAR) - Defense World
Comparing Tharimmune (NASDAQ:THAR) and Phio Pharmaceuticals (NASDAQ:PHIO) - Defense World
Tharimmune (NASDAQ:THAR) and Cara Therapeutics (NASDAQ:CARA) Head-To-Head Review - Armenian Reporter
Comparing Cara Therapeutics (NASDAQ:CARA) & Tharimmune (NASDAQ:THAR) - Defense World
Larchmont broker accused of years-long insider trading scheme - Westfair Communications
Tharimmune (NASDAQ:THAR) Trading 3% Higher – Should You Buy? - Defense World
0.24%
36.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):